Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Completed 13Active not recruiting 5Terminated 4Withdrawn 2Unknown 2Recruiting 2Suspended 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2Lymphoid 2Dermatologic 1

Conditions

Small Cell Lung Carcinoma 27Lymphoma, Large B-Cell, Diffuse 10Lung Neoplasms 8Precursor Cell Lymphoblastic Leukemia-Lymphoma 6Lymphoma, Non-Hodgkin 6Lymphoma, B-Cell 6Hodgkin Disease 6Burkitt Lymphoma 6Neuroblastoma 5Medulloblastoma 5Neoplasms, Germ Cell and Embryonal 4Leukemia, Myeloid, Acute 4Small Cell Lung Cancer Extensive Stage 3Seminoma 3Retinoblastoma 3Recurrence 3Ovarian Neoplasms 3Multiple Myeloma 3Lymphoma 3Carcinoma, Neuroendocrine 3Brain Neoplasms 3Wilms Tumor 2Urinary Bladder Neoplasms 2Teratoma 2Sarcoma, Ewing 2Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 2Plasmablastic Lymphoma 2Neuroectodermal Tumors, Primitive 2Lymphoma, T-Cell 2Lymphoma, Mantle-Cell 2

Interventions

Cyclophosphamide 11venetoclax 10Dexamethasone 8Cytarabine 7Vincristine 5Azacitidine 4mogamulizumab 3fludarabine phosphate 3fludarabine 3daratumumab 3Specimen Handling 3Prednisone 3Methotrexate 3Doxorubicin 3Dasatinib 3Biopsy 3ruxolitinib 2prednylidene 2pegaspargase 2nelarabine 2deltacortene 2calaspargase pegol 2Rituximab 2Mercaptopurine 2Etoposide 2Decitabine 2Daunorubicin 2Calcium Dobesilate 2Bortezomib 2Asparaginase 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Recruiting × Precursor T-Cell Lymphoblastic Leukemia-Lymphoma × Etoposide × Clear all
NCT06738368 2026-05-12

Etoposide, Prednisone, Vincristine, Cyclophosphamide, and Doxorubicin (DA-EPOCH) With or Without Rituximab Plus Recombinant Erwinia Asparaginase (JZP458) for the Treatment of Newly Diagnosed Ph Negative B-Acute Lymphoblastic Leukemia or T Acute Lymphoblastic Leukemia

University of Washington

Phase 2 Recruiting
30 enrolled
LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

NCT05996185 2026-04-14

Study of Mogamulizumab With DA-EPOCH or CHOEP in Patients With Aggressive T-cell Lymphoma

Yale University

Phase 2 Recruiting
22 enrolled
DermatologicLymphoidOther hematologic neoplasm

Recurrence, Lymphoma, T-Cell, Lymphoma, T-Cell, Cutaneous, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡